Multitarget tyrosine kinase inhibition: ''And the winner is ..."

被引：11
|
作者：
Verweij, Jaap [1 ]
de Jonge, Maja [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 17期
关键词：
D O I：
10.1200/JCO.2007.10.7318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2340 / 2342
页数：3
相关论文
共 50 条
  • [1] Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms
    Grillo, Federica
    Florio, Tullio
    Ferrau, Francesco
    Kara, Elda
    Fanciulli, Giuseppe
    Faggiano, Antongiulio
    Colao, Annamaria
    ENDOCRINE-RELATED CANCER, 2018, 25 (09) : R453 - R466
  • [2] Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond
    Bologna, M.
    Vicentini, C.
    Muzi, P.
    Pace, G.
    Angelucci, A.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (19) : 2827 - 2835
  • [3] Prevention of Venous Neointimal Hyperplasia by a Multitarget Receptor Tyrosine Kinase Inhibitor
    Kwon, Sun Hyung
    Li, Li
    He, Yuxia
    Tey, Jason Chieh Sheng
    Li, Huan
    Zhuplatov, Ilya
    Kim, Seung-Jung
    Terry, Christi M.
    Blumenthal, Donald K.
    Shiu, Yan-Ting
    Cheung, Alfred K.
    JOURNAL OF VASCULAR RESEARCH, 2015, 52 (04) : 244 - 256
  • [4] Tyrosine kinase inhibition and grey hair
    Robert, C
    Spatz, A
    Faivre, S
    Armand, JP
    Raymond, E
    LANCET, 2003, 361 (9362): : 1056 - 1056
  • [5] Economical and Practical Process Development for a Novel Multitarget Tyrosine Kinase Inhibitor Vorolanib
    Xiu, Xiaomeng
    Jia, Hongwei
    Liu, Yaoyang
    Zhao, Xueqi
    Liu, Yang
    Yang, Huali
    Cheng, Maosheng
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2024, 28 (02) : 492 - 499
  • [6] Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny
    Minotti, Giorgio
    Camilli, Massimiliano
    Salvatorelli, Emanuela
    Menna, Pierantonio
    BRITISH JOURNAL OF PHARMACOLOGY, 2025, 182 (07) : 1446 - 1451
  • [7] Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL
    L Lhermitte
    R Ben Abdelali
    P Villarèse
    N Bedjaoui
    V Guillemot
    A Trinquand
    M Libura
    A S Bedin
    A Petit
    H Dombret
    G Leverger
    N Ifrah
    O Hermine
    E Macintyre
    V Asnafi
    Leukemia, 2013, 27 : 305 - 314
  • [8] Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL
    Lhermitte, L.
    Ben Abdelali, R.
    Villarese, P.
    Bedjaoui, N.
    Guillemot, V.
    Trinquand, A.
    Libura, M.
    Bedin, A. S.
    Petit, A.
    Dombret, H.
    Leverger, G.
    Ifrah, N.
    Hermine, O.
    Macintyre, E.
    Asnafi, V.
    LEUKEMIA, 2013, 27 (02) : 305 - 314
  • [9] INHIBITION OF PLATELET ACTIVATION BY TYROSINE KINASE INHIBITORS
    RENDU, F
    ELDOR, A
    GRELAC, F
    BACHELOT, C
    GAZIT, A
    GILON, C
    LEVYTOLEDANO, S
    LEVITZKI, A
    BIOCHEMICAL PHARMACOLOGY, 1992, 44 (05) : 881 - 888
  • [10] TYROSINE KINASE INHIBITION - AN APPROACH TO DRUG DEVELOPMENT
    LEVITZKI, A
    GAZIT, A
    SCIENCE, 1995, 267 (5205) : 1782 - 1788
12345